Translumina Therapeutics LLP has presented a 10-year patient safety and efficacy data of its drug-eluting stent (DES) Yukon Choice PC, recently.
The research findings of a randomized control trial called ISAR-TEST 4 were presented by leading cardiac expert from Germany, Dr. Sebastian Kufner at the 2018 American Heart Association Scientific Sessions at Chicago, Illinois, United States.
The trial compared Yukon Choice PC against Xience (manufactured by Abbott Vascular, USA) in 2603 patients in Germany for a follow-up period of 10 years. The data demonstrated that at 10 years, both Indian made Yukon Choice PC and much used USFDA approved Xience stents showed significantly better results than the
Cypher stent regarding major adverse cardiac events, with a risk reduction of 18% and 21% and mortality risk reduction of 18% and 22%, respectively. There were no significant differences between Yukon Choice PC and Xience stents regarding these outcomes.
However, Yukon Choice PC showed the lowest rate of definite or probable stent thrombosis with a significant risk reduction than the Cypher stent (50% reduction) and even a numerically lower rate than the Xience stent (29% reduction).
Yukon Choice PC uses a technology combining special surface modification and low polymeric load for controlled and optimal release kinetics of an anti-proliferative drug.
Yukon Choice PC stents are manufactured at the Dehradun facility of Translumina Therapeutics.